Copyright Reports & Markets. All rights reserved.

Global Mesalamine API Sales Market Report 2021

Request for Sample of this report
Buy now

1 Mesalamine API Market Overview

  • 1.1 Mesalamine API Product Scope
  • 1.2 Mesalamine API Segment by Type
    • 1.2.1 Global Mesalamine API Sales by Type (2016 & 2021 & 2027)
    • 1.2.2 Purity ≥ 97 %
    • 1.2.3 Purity ≥ 98 %
    • 1.2.4 Purity ≥ 99 %
  • 1.3 Mesalamine API Segment by Application
    • 1.3.1 Global Mesalamine API Sales Comparison by Application (2016 & 2021 & 2027)
    • 1.3.2 Mesalamine Tablets
    • 1.3.3 Mesalamine Capsules
    • 1.3.4 Others
  • 1.4 Mesalamine API Market Estimates and Forecasts (2016-2027)
    • 1.4.1 Global Mesalamine API Market Size in Value Growth Rate (2016-2027)
    • 1.4.2 Global Mesalamine API Market Size in Volume Growth Rate (2016-2027)
    • 1.4.3 Global Mesalamine API Price Trends (2016-2027)

2 Mesalamine API Estimates and Forecasts by Region

  • 2.1 Global Mesalamine API Market Size by Region: 2016 VS 2021 VS 2027
  • 2.2 Global Mesalamine API Retrospective Market Scenario by Region (2016-2021)
    • 2.2.1 Global Mesalamine API Sales Market Share by Region (2016-2021)
    • 2.2.2 Global Mesalamine API Revenue Market Share by Region (2016-2021)
  • 2.3 Global Mesalamine API Market Estimates and Forecasts by Region (2022-2027)
    • 2.3.1 Global Mesalamine API Sales Estimates and Forecasts by Region (2022-2027)
    • 2.3.2 Global Mesalamine API Revenue Forecast by Region (2022-2027)
  • 2.4 Geographic Market Analysis: Market Facts & Figures
    • 2.4.1 North America Mesalamine API Estimates and Projections (2016-2027)
    • 2.4.2 Europe Mesalamine API Estimates and Projections (2016-2027)
    • 2.4.3 China Mesalamine API Estimates and Projections (2016-2027)
    • 2.4.4 Japan Mesalamine API Estimates and Projections (2016-2027)
    • 2.4.5 Southeast Asia Mesalamine API Estimates and Projections (2016-2027)
    • 2.4.6 India Mesalamine API Estimates and Projections (2016-2027)

3 Global Mesalamine API Competition Landscape by Players

  • 3.1 Global Top Mesalamine API Players by Sales (2016-2021)
  • 3.2 Global Top Mesalamine API Players by Revenue (2016-2021)
  • 3.3 Global Mesalamine API Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Mesalamine API as of 2020)
  • 3.4 Global Mesalamine API Average Price by Company (2016-2021)
  • 3.5 Manufacturers Mesalamine API Manufacturing Sites, Area Served, Product Type
  • 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Mesalamine API Market Size by Type

  • 4.1 Global Mesalamine API Historic Market Review by Type (2016-2021)
    • 4.1.1 Global Mesalamine API Sales Market Share by Type (2016-2021)
    • 4.1.2 Global Mesalamine API Revenue Market Share by Type (2016-2021)
    • 4.1.3 Global Mesalamine API Price by Type (2016-2021)
  • 4.2 Global Mesalamine API Market Estimates and Forecasts by Type (2022-2027)
    • 4.2.1 Global Mesalamine API Sales Forecast by Type (2022-2027)
    • 4.2.2 Global Mesalamine API Revenue Forecast by Type (2022-2027)
    • 4.2.3 Global Mesalamine API Price Forecast by Type (2022-2027)

5 Global Mesalamine API Market Size by Application

  • 5.1 Global Mesalamine API Historic Market Review by Application (2016-2021)
    • 5.1.1 Global Mesalamine API Sales Market Share by Application (2016-2021)
    • 5.1.2 Global Mesalamine API Revenue Market Share by Application (2016-2021)
    • 5.1.3 Global Mesalamine API Price by Application (2016-2021)
  • 5.2 Global Mesalamine API Market Estimates and Forecasts by Application (2022-2027)
    • 5.2.1 Global Mesalamine API Sales Forecast by Application (2022-2027)
    • 5.2.2 Global Mesalamine API Revenue Forecast by Application (2022-2027)
    • 5.2.3 Global Mesalamine API Price Forecast by Application (2022-2027)

6 North America Mesalamine API Market Facts & Figures

  • 6.1 North America Mesalamine API Sales by Company
    • 6.1.1 North America Mesalamine API Sales by Company (2016-2021)
    • 6.1.2 North America Mesalamine API Revenue by Company (2016-2021)
  • 6.2 North America Mesalamine API Sales Breakdown by Type
    • 6.2.1 North America Mesalamine API Sales Breakdown by Type (2016-2021)
    • 6.2.2 North America Mesalamine API Sales Breakdown by Type (2022-2027)
  • 6.3 North America Mesalamine API Sales Breakdown by Application
    • 6.3.1 North America Mesalamine API Sales Breakdown by Application (2016-2021)
    • 6.3.2 North America Mesalamine API Sales Breakdown by Application (2022-2027)

7 Europe Mesalamine API Market Facts & Figures

  • 7.1 Europe Mesalamine API Sales by Company
    • 7.1.1 Europe Mesalamine API Sales by Company (2016-2021)
    • 7.1.2 Europe Mesalamine API Revenue by Company (2016-2021)
  • 7.2 Europe Mesalamine API Sales Breakdown by Type
    • 7.2.1 Europe Mesalamine API Sales Breakdown by Type (2016-2021)
    • 7.2.2 Europe Mesalamine API Sales Breakdown by Type (2022-2027)
  • 7.3 Europe Mesalamine API Sales Breakdown by Application
    • 7.3.1 Europe 141 Sales Breakdown by Application (2016-2021)
    • 7.3.2 Europe 141 Sales Breakdown by Application (2022-2027)

8 China Mesalamine API Market Facts & Figures

  • 8.1 China Mesalamine API Sales by Company
    • 8.1.1 China Mesalamine API Sales by Company (2016-2021)
    • 8.1.2 China Mesalamine API Revenue by Company (2016-2021)
  • 8.2 China Mesalamine API Sales Breakdown by Type
    • 8.2.1 China Mesalamine API Sales Breakdown by Type (2016-2021)
    • 8.2.2 China Mesalamine API Sales Breakdown by Type (2022-2027)
  • 8.3 China Mesalamine API Sales Breakdown by Application
    • 8.3.1 China 315 Sales Breakdown by Application (2016-2021)
    • 8.3.2 China 315 Sales Breakdown by Application (2022-2027)

9 Japan Mesalamine API Market Facts & Figures

  • 9.1 Japan Mesalamine API Sales by Company
    • 9.1.1 Japan Mesalamine API Sales by Company (2016-2021)
    • 9.1.2 Japan Mesalamine API Revenue by Company (2016-2021)
  • 9.2 Japan Mesalamine API Sales Breakdown by Type
    • 9.2.1 Japan Mesalamine API Sales Breakdown by Type (2016-2021)
    • 9.2.2 Japan Mesalamine API Sales Breakdown by Type (2022-2027)
  • 9.3 Japan Mesalamine API Sales Breakdown by Application
    • 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
    • 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Mesalamine API Market Facts & Figures

  • 10.1 Southeast Asia Mesalamine API Sales by Company
    • 10.1.1 Southeast Asia Mesalamine API Sales by Company (2016-2021)
    • 10.1.2 Southeast Asia Mesalamine API Revenue by Company (2016-2021)
  • 10.2 Southeast Asia Mesalamine API Sales Breakdown by Type
    • 10.2.1 Southeast Asia Mesalamine API Sales Breakdown by Type (2016-2021)
    • 10.2.2 Southeast Asia Mesalamine API Sales Breakdown by Type (2022-2027)
  • 10.3 Southeast Asia Mesalamine API Sales Breakdown by Application
    • 10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
    • 10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)

11 India Mesalamine API Market Facts & Figures

  • 11.1 India Mesalamine API Sales by Company
    • 11.1.1 India Mesalamine API Sales by Company (2016-2021)
    • 11.1.2 India Mesalamine API Revenue by Company (2016-2021)
  • 11.2 India Mesalamine API Sales Breakdown by Type
    • 11.2.1 India Mesalamine API Sales Breakdown by Type (2016-2021)
    • 11.2.2 India Mesalamine API Sales Breakdown by Type (2022-2027)
  • 11.3 India Mesalamine API Sales Breakdown by Application
    • 11.3.1 India Mesalamine API Sales Breakdown by Application (2016-2021)
    • 11.3.2 India Mesalamine API Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Mesalamine API Business

  • 12.1 Syntese A/S
    • 12.1.1 Syntese A/S Corporation Information
    • 12.1.2 Syntese A/S Business Overview
    • 12.1.3 Syntese A/S Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.1.4 Syntese A/S Mesalamine API Products Offered
    • 12.1.5 Syntese A/S Recent Development
  • 12.2 Divis Laboratories
    • 12.2.1 Divis Laboratories Corporation Information
    • 12.2.2 Divis Laboratories Business Overview
    • 12.2.3 Divis Laboratories Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.2.4 Divis Laboratories Mesalamine API Products Offered
    • 12.2.5 Divis Laboratories Recent Development
  • 12.3 Cambrex Corporation
    • 12.3.1 Cambrex Corporation Corporation Information
    • 12.3.2 Cambrex Corporation Business Overview
    • 12.3.3 Cambrex Corporation Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.3.4 Cambrex Corporation Mesalamine API Products Offered
    • 12.3.5 Cambrex Corporation Recent Development
  • 12.4 Ipca Laboratories
    • 12.4.1 Ipca Laboratories Corporation Information
    • 12.4.2 Ipca Laboratories Business Overview
    • 12.4.3 Ipca Laboratories Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.4.4 Ipca Laboratories Mesalamine API Products Offered
    • 12.4.5 Ipca Laboratories Recent Development
  • 12.5 PharmaZell
    • 12.5.1 PharmaZell Corporation Information
    • 12.5.2 PharmaZell Business Overview
    • 12.5.3 PharmaZell Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.5.4 PharmaZell Mesalamine API Products Offered
    • 12.5.5 PharmaZell Recent Development
  • 12.6 Lasa Loboratory
    • 12.6.1 Lasa Loboratory Corporation Information
    • 12.6.2 Lasa Loboratory Business Overview
    • 12.6.3 Lasa Loboratory Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.6.4 Lasa Loboratory Mesalamine API Products Offered
    • 12.6.5 Lasa Loboratory Recent Development
  • 12.7 Erregierre SpA
    • 12.7.1 Erregierre SpA Corporation Information
    • 12.7.2 Erregierre SpA Business Overview
    • 12.7.3 Erregierre SpA Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.7.4 Erregierre SpA Mesalamine API Products Offered
    • 12.7.5 Erregierre SpA Recent Development
  • 12.8 Corden Pharma Bergamo
    • 12.8.1 Corden Pharma Bergamo Corporation Information
    • 12.8.2 Corden Pharma Bergamo Business Overview
    • 12.8.3 Corden Pharma Bergamo Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.8.4 Corden Pharma Bergamo Mesalamine API Products Offered
    • 12.8.5 Corden Pharma Bergamo Recent Development
  • 12.9 CTX Lifescience
    • 12.9.1 CTX Lifescience Corporation Information
    • 12.9.2 CTX Lifescience Business Overview
    • 12.9.3 CTX Lifescience Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.9.4 CTX Lifescience Mesalamine API Products Offered
    • 12.9.5 CTX Lifescience Recent Development
  • 12.10 Ishita Active Pharma Ingredients
    • 12.10.1 Ishita Active Pharma Ingredients Corporation Information
    • 12.10.2 Ishita Active Pharma Ingredients Business Overview
    • 12.10.3 Ishita Active Pharma Ingredients Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.10.4 Ishita Active Pharma Ingredients Mesalamine API Products Offered
    • 12.10.5 Ishita Active Pharma Ingredients Recent Development
  • 12.11 YC Biotech (Jiangsu)
    • 12.11.1 YC Biotech (Jiangsu) Corporation Information
    • 12.11.2 YC Biotech (Jiangsu) Business Overview
    • 12.11.3 YC Biotech (Jiangsu) Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.11.4 YC Biotech (Jiangsu) Mesalamine API Products Offered
    • 12.11.5 YC Biotech (Jiangsu) Recent Development
  • 12.12 Xinxiang Tianfeng Fine Chemical
    • 12.12.1 Xinxiang Tianfeng Fine Chemical Corporation Information
    • 12.12.2 Xinxiang Tianfeng Fine Chemical Business Overview
    • 12.12.3 Xinxiang Tianfeng Fine Chemical Mesalamine API Sales, Revenue and Gross Margin (2016-2021)
    • 12.12.4 Xinxiang Tianfeng Fine Chemical Mesalamine API Products Offered
    • 12.12.5 Xinxiang Tianfeng Fine Chemical Recent Development

13 Mesalamine API Manufacturing Cost Analysis

  • 13.1 Mesalamine API Key Raw Materials Analysis
    • 13.1.1 Key Raw Materials
    • 13.1.2 Key Raw Materials Price Trend
    • 13.1.3 Key Suppliers of Raw Materials
  • 13.2 Proportion of Manufacturing Cost Structure
  • 13.3 Manufacturing Process Analysis of Mesalamine API
  • 13.4 Mesalamine API Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers

  • 14.1 Marketing Channel
  • 14.2 Mesalamine API Distributors List
  • 14.3 Mesalamine API Customers

15 Market Dynamics

  • 15.1 Mesalamine API Market Trends
  • 15.2 Mesalamine API Drivers
  • 15.3 Mesalamine API Market Challenges
  • 15.4 Mesalamine API Market Restraints

16 Research Findings and Conclusion

    17 Appendix

    • 17.1 Research Methodology
      • 17.1.1 Methodology/Research Approach
      • 17.1.2 Data Source
    • 17.2 Author List

    Mesalamine was approved for medical use in the United States in 1987. Mesalamine, also known as mesalazine or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.

    Market Analysis and Insights: Global Mesalamine API Market
    The global Mesalamine API market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

    Global Mesalamine API Scope and Market Size
    The global Mesalamine API market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Mesalamine API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

    Segment by Type
    Purity ≥ 97 %
    Purity ≥ 98 %
    Purity ≥ 99 %

    Segment by Application
    Mesalamine Tablets
    Mesalamine Capsules
    Others

    The Mesalamine API market is analysed and market size information is provided by regions (countries). Segment by Application, the Mesalamine API market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

    By Company
    Syntese A/S
    Divis Laboratories
    Cambrex Corporation
    Ipca Laboratories
    PharmaZell
    Lasa Loboratory
    Erregierre SpA
    Corden Pharma Bergamo
    CTX Lifescience
    Ishita Active Pharma Ingredients
    YC Biotech (Jiangsu)
    Xinxiang Tianfeng Fine Chemical

    Buy now